Literature DB >> 24339736

Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis.

Yunzhou Shi1, Jason Oeh, Jeffrey Eastham-Anderson, Sharon Yee, David Finkle, Franklin V Peale, Jed Ross, Maj Hedehus, Nicholas van Bruggen, Rayna Venook, Sarajane Ross, Deepak Sampath, Richard A D Carano.   

Abstract

Quantifying oxygenation in viable tumor remains a major obstacle toward a better understanding of the tumor micro-environment and improving treatment strategies. Current techniques are often complicated by tumor heterogeneity. Herein, a novel in vivo approach that combines (19)F magnetic resonance imaging ((19)F-MRI) R 1 mapping with diffusion-based multispectral (MS) analysis is introduced. This approach restricts the partial pressure of oxygen (pO2) measurements to viable tumor, the tissue of therapeutic interest. The technique exhibited sufficient sensitivity to detect a breathing gas challenge in a xenograft tumor model, and the hypoxic region measured by MS (19)F-MRI was strongly correlated with histologic estimates of hypoxia. This approach was then applied to address the effects of antivascular agents on tumor oxygenation, which is a research question that is still under debate. The technique was used to monitor longitudinal pO2 changes in response to an antibody to vascular endothelial growth factor (B20.4.1.1) and a selective dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor (GDC-0980). GDC-0980 reduced viable tumor pO2 during a 3-day treatment period, and a significant reduction was also produced by B20.4.1.1. Overall, this method provides an unprecedented view of viable tumor pO2 and contributes to a greater understanding of the effects of antivascular therapies on the tumor's microenvironment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24339736      PMCID: PMC3858898          DOI: 10.1593/neo.131468

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  33 in total

1.  MRI of perfluorocarbon emulsion kinetics in rodent mammary tumours.

Authors:  Xiaobing Fan; Jonathan N River; Adrian S Muresan; Carmen Popescu; Marta Zamora; Rita M Culp; Gregory S Karczmar
Journal:  Phys Med Biol       Date:  2005-12-21       Impact factor: 3.609

Review 2.  19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance.

Authors:  Jian-xin Yu; Vikram D Kodibagkar; Weina Cui; Ralph P Mason
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

3.  Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Authors:  Wei-Ching Liang; Xiumin Wu; Franklin V Peale; Chingwei V Lee; Y Gloria Meng; Johnny Gutierrez; Ling Fu; Ajay K Malik; Hans-Peter Gerber; Napoleone Ferrara; Germaine Fuh
Journal:  J Biol Chem       Date:  2005-11-07       Impact factor: 5.157

4.  Novel 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane.

Authors:  Vikram D Kodibagkar; Weina Cui; Matthew E Merritt; Ralph P Mason
Journal:  Magn Reson Med       Date:  2006-04       Impact factor: 4.668

5.  Characterization and validation of noninvasive oxygen tension measurements in human glioma xenografts by 19F-MR relaxometry.

Authors:  B P van der Sanden; A Heerschap; A W Simonetti; P F Rijken; H P Peters; G Stüben; A J van der Kogel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

6.  Regional tumor oxygen tension: fluorine echo planar imaging of hexafluorobenzene reveals heterogeneity of dynamics.

Authors:  R P Mason; S Hunjan; D Le; A Constantinescu; B R Barker; P S Wong; P Peschke; E W Hahn; P P Antich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-11-01       Impact factor: 7.038

7.  Rapid monitoring of oxygenation by 19F magnetic resonance imaging: Simultaneous comparison with fluorescence quenching.

Authors:  Bénédicte F Jordan; Greg O Cron; Bernard Gallez
Journal:  Magn Reson Med       Date:  2009-03       Impact factor: 4.668

8.  Quantification of viable tumor microvascular characteristics by multispectral analysis.

Authors:  Leanne R Berry; Kai H Barck; Mary Ann Go; Jed Ross; Xiumin Wu; Simon P Williams; Alvin Gogineni; Mary J Cole; Nicholas Van Bruggen; Germaine Fuh; Frank Peale; Napoleone Ferrara; Sarajane Ross; Ralph H Schwall; Richard A D Carano
Journal:  Magn Reson Med       Date:  2008-07       Impact factor: 4.668

9.  Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.

Authors:  Annamaria Rapisarda; Melinda Hollingshead; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Bradley Gehrs; Mark Raffeld; Robert J Kinders; Ralph Parchment; Miriam R Anver; Robert H Shoemaker; Giovanni Melillo
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

10.  Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

Authors:  Ruud P M Dings; Melissa Loren; Hanke Heun; Elizabeth McNiel; Arjan W Griffioen; Kevin H Mayo; Robert J Griffin
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

View more
  13 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Simultaneous spatiotemporal tracking and oxygen sensing of transient implants in vivo using hot-spot MRI and machine learning.

Authors:  Virginia Spanoudaki; Joshua C Doloff; Wei Huang; Samuel R Norcross; Shady Farah; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-26       Impact factor: 11.205

Review 3.  New frontiers and developing applications in 19F NMR.

Authors:  Jian-Xin Yu; Rami R Hallac; Srinivas Chiguru; Ralph P Mason
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2012-11-02       Impact factor: 9.795

Review 4.  Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI.

Authors:  James P B O'Connor; Simon P Robinson; John C Waterton
Journal:  Br J Radiol       Date:  2019-01-24       Impact factor: 3.039

Review 5.  Biomarkers in preclinical cancer imaging.

Authors:  Monique R Bernsen; Klazina Kooiman; Marcel Segbers; Fijs W B van Leeuwen; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

6.  Porphyromonas gingivalis-Derived Lipopolysaccharide Combines Hypoxia to Induce Caspase-1 Activation in Periodontitis.

Authors:  Ran Cheng; Wen Liu; Rui Zhang; Yuchao Feng; Neil A Bhowmick; Tao Hu
Journal:  Front Cell Infect Microbiol       Date:  2017-11-14       Impact factor: 5.293

7.  Tracking Perfluorocarbon Nanoemulsion Delivery by 19F MRI for Precise High Intensity Focused Ultrasound Tumor Ablation.

Authors:  Soo Hyun Shin; Eun-Joo Park; Changki Min; Sun Il Choi; Soyeon Jeon; Yun-Hee Kim; Daehong Kim
Journal:  Theranostics       Date:  2017-01-07       Impact factor: 11.556

Review 8.  Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical Settings.

Authors:  Florence Colliez; Bernard Gallez; Bénédicte F Jordan
Journal:  Front Oncol       Date:  2017-01-25       Impact factor: 6.244

9.  Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by 19F-MRI and Multispectral Analysis.

Authors:  Yunzhou Shi; Jason Oeh; Anna Hitz; Maj Hedehus; Jeffrey Eastham-Anderson; Franklin V Peale; Patricia Hamilton; Thomas O'Brien; Deepak Sampath; Richard A D Carano
Journal:  Neoplasia       Date:  2017-10-06       Impact factor: 5.715

10.  Monitoring the Process of Endostar-Induced Tumor Vascular Normalization by Non-contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI.

Authors:  Jing-Hua Pan; Shengbin Zhu; Jinlian Huang; Jianye Liang; Dong Zhang; Xiaoxu Zhao; Hui Ding; Li Qin; Changzheng Shi; Liangping Luo; Yunlong Pan
Journal:  Front Oncol       Date:  2018-11-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.